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OBJECTIVE — Diabeteshaslongbeenrecognizedasariskfactorforatrialﬁbrillation,butits
independent contribution to atrial ﬁbrillation has not been fully evaluated. We sought to com-
paretheprevalenceandincidenceofatrialﬁbrillationinage-andsex-matchedpatientswithand
without type 2 diabetes.
RESEARCH DESIGN AND METHODS — Using an observational cohort design, we
selected 10,213 members of an HMO diabetes registry as of 1 January 1999 plus 7,159 patients
who entered the registry by 31 December 2004 and matched them to patients without diabetes
on year of birth and sex. All patients were followed until they died, left the health plan, or until
31December2008.Wecomparedthebaselineprevalenceofatrialﬁbrillationandthenfollowed
patients without atrial ﬁbrillation to compare atrial ﬁbrillation incidence while controlling for
known risk factors.
RESULTS — Atrial ﬁbrillation prevalence was signiﬁcantly greater among patients with dia-
betes (3.6 vs. 2.5%, P  0.0001). Over a mean follow-up of 7.2  2.8 years, diabetic patients
without atrial ﬁbrillation at baseline developed atrial ﬁbrillation at an age- and sex-adjusted rate
of 9.1 per 1,000 person-years (95% CI 8.6–9.7) compared with a rate of 6.6 (6.2–7.1) among
nondiabetic patients. After full adjustment for other risk factors, diabetes was associated with a
26% increased risk of atrial ﬁbrillation among women (hazard ratio 1.26 [95% CI 1.08–1.46]),
but diabetes was not a statistically signiﬁcant factor among men (1.09 [0.96–1.24]).
CONCLUSIONS — In this population, diabetes was an independent determinant of atrial
ﬁbrillation prevalence but predicted incidence only among women. These ﬁndings have poten-
tial public health implications and emphasize the need for further investigation of the mecha-
nistic links between diabetes and atrial ﬁbrillation.
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M
ore than 23 million U.S. adults
have diabetes (1), a ﬁgure that is
growing by 1 million each year
(2). An additional 57 million U.S. resi-
dents are estimated to have pre-diabetes
(1). Atrial ﬁbrillation, the most common
arrhythmiadiagnosisintheworld,afﬂicts
approximately2.2millionU.S.adults(3),
and that number could more than double
by 2050 (4). Other analyses have shown
that the rising prevalence and incidence
of atrial ﬁbrillation cannot be explained
by aging alone (5,6). Recent ﬁndings in-
dicate that atrial ﬁbrillation may be rela-
tively common in diabetic patients and
should be regarded as a marker of partic-
ularly adverse outcomes, prompting ag-
gressive management of all risk factors
(7). The overlap of diabetes and atrial
ﬁbrillation also contributes to a well-
established increased risk of thromboem-
bolic stroke (8).
Although diabetes and atrial ﬁbrilla-
tion undoubtedly share common ante-
cedents such as hypertension,
atherosclerosis, and obesity (9–11), the
conﬂuenceofthesetwoconditionsclearly
warrants additional study. Diabetes has
long been recognized as a risk factor for
atrial ﬁbrillation (12), which was subse-
quently reafﬁrmed in several studies
(10,13,14). However, the potential inde-
pendent contribution of diabetes to the
prevalence and incidence of atrial ﬁbrilla-
tion has not been evaluated. We therefore
performed comparative analyses of the
prevalence and incidence of atrial ﬁbril-
lation in patients with and without
diabetes.
RESEARCH DESIGN AND
METHODS— The study site was Kai-
ser Permanente Northwest (KPNW), a
480,000-member group-model HMO
thatusesclinicalpracticeguidelinestoas-
sist clinicians with patient management.
We used an observational longitudinal
study design that capitalizes on the com-
prehensive medical utilization data main-
tained by KPNW, including an electronic
medical record of all patient encounters,
laboratory results that are analyzed by a
singleregionallaboratoryusingstandard-
ized methods, and dispenses from phar-
macies located in all clinics. The
institutional review board of the Kaiser
Permanente Center for Health Research
reviewed and approved the study.
Sample selection
Since 1989, KPNW has maintained a reg-
istryofpatientswithknowndiabetes.The
criteria for registry entry include an inpa-
tient or outpatient diagnosis of diabetes
(ICD-9-CM codes 250.xx), use of an an-
tihyperglycemic drug, or at least two
blood glucose test results above diagnos-
tic levels for diabetes. For the current
study, we selected 10,213 patients who
were members of the diabetes registry as
of1January1999and7,159patientswho
enteredtheregistryby31December2004
(total17,372),deﬁningthestudyindex
date as either 1 January 1999 (for pre-
1999 registrants) or date of registry entry.
WethenmatchedthesepatientstoKPNW
members without diabetes on year of
birth and sex. For these nondiabetic sub-
jects,wedeﬁnedtheirindexdateasthatof
their matched diabetic subject. The prev-
alence of atrial ﬁbrillation was calculated
asoftheindexdate.Toconductincidence
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alent atrial ﬁbrillation and 1,143 patients
who had a history of stroke. The remain-
ing patients were then followed until they
died, left the health plan, or until 31 De-
cember 2008, whichever came ﬁrst.
Outcomes and covariates
Patients were identiﬁed with prevalent
atrial ﬁbrillation if they had a diagnosis
(ICD-9-CM427.31)recordedinthemed-
ical record on or before their index date.
Incident diagnoses were similarly identi-
ﬁed any time after index until the end of
follow-up among those patients who did
not have prevalent atrial ﬁbrillation. We
also identiﬁed comorbidities present at
baseline (ICD-9-CM code), including
ischemic heart disease (410.x–414.x),
history of stroke or cerebrovascular dis-
ease (430.x, 431.x, 432.x, 434.x, 435.x,
436.x, and 437.1), valvular disease
(424.0–424.3), heart failure (428.x), hy-
pertension (401.x–405.x), and history of
depression (296.2x, 296.3x, 300.4,
309.1, and 311). Height, weight, and
blood pressure were captured in the elec-
tronic medical record: for this study,
baseline values of weight and blood pres-
sure were the last measures before the in-
dex date. Baseline laboratory values,
including LDL cholesterol, HDL choles-
terol, triglycerides, serum creatinine (for
estimation of glomerular ﬁltration rate),
and A1C (among patients with diabetes)
were also those recorded latest on or be-
fore index date.
Statistical analyses
We conducted bivariate comparisons of
baseline covariates among patients with
and without diabetes using t tests for
continuous variables and 
2 tests for cat-
egorical variables. We calculated and
compared age- and sex-adjusted inci-
dence rates of atrial ﬁbrillation per 1,000
person-years using regression for inci-
dence densities. We then used Cox pro-
portional hazards regression analysis to
determine risk of incident atrial ﬁbrilla-
tionfordiabetes,controllingforotherrisk
factors. All analyses were conducted with
SAS (version 8.2; SAS Institute, Cary,
NC).
RESULTS— Mean age of the study
samplewas58.411.5years,and51.2%
were men (Table 1). Patients with diabe-
tes were more likely to be nonwhite (11.9
vs. 6.4%, P  0.0001), to have a higher
BMI (33.6  7.3 vs. 28.9  5.7 kg/m
2,
P  0.0001), and to have higher blood
pressure (136/80 vs. 132/79 mmHg, P 
0.0001). Comorbidities were more com-
mon among patients with diabetes, in-
cluding ischemic heart disease (10.6 vs.
9.8%, P  0.014), history of stroke (4.4
vs. 2.9%, P  0.0001), hypertension
(47.1 vs. 26.9%, P  0.0001), heart fail-
ure (4.4 vs. 1.8%, P  0.0001), and his-
tory of depression (15.8 vs. 11.7%, P 
0.0001).
The prevalence of atrial ﬁbrillation
was signiﬁcantly greater among patients
with diabetes (3.6 vs. 2.5%, P  0.0001)
(Fig. 1A). Prevalence increased with age
inbothgroupsbutwassigniﬁcantlyexag-
gerated among diabetic patients. These
same relationships were observed among
men (Fig. 1B) and women (Fig. 1C). Al-
though men had a higher prevalence of
atrial ﬁbrillation in all age-groups regard-
less of diabetes, the difference in preva-
lence between those with and without
diabetes was greater in women than in
men. For example, among men aged
65–74 years, atrial ﬁbrillation was 30%
more prevalent among patients with dia-
betes (7.9 vs. 6.1%, P  0.037). Among
women, atrial ﬁbrillation prevalence was
61% higher in diabetic patients in the
65–74yearsage-group(6.1vs.3.8%,P
0.002).
Over a mean follow-up of 7.2  2.8
years, the 16,057 diabetic patients with-
outprevalentatrialﬁbrillationorahistory
of stroke at baseline developed atrial ﬁ-
brillation at an age- and sex-adjusted in-
cidencerateof9.1per1,000person-years
(95%CI8.6–9.7)comparedwitharateof
6.6 (6.2–7.1) among the 16,471 nondia-
betic patients (Fig. 2A). Thus, the age-
and sex-adjusted relative risk of atrial ﬁ-
brillation was 38% (28–49%) greater
among individuals with diabetes. Among
men, the age-adjusted incidence of atrial
ﬁbrillation per 1,000 person-years was
10.8 (9.9–11.7) and 8.3 (7.6–9.1), re-
spectively, for patients with and without
diabetes (Fig. 1B), producing a 30% (17–
43%) greater relative risk among men
with diabetes. Among women, age-
adjusted atrial ﬁbrillation incidence was
7.6 (6.9–8.4) and 5.0 (4.5–5.6), respec-
tively (Fig. 1C), with a higher relative
risk attributable to diabetes of 52%
(34–70%).
Table 2 displays the Cox regression
models of time to development of atrial
ﬁbrillation. After controls were included
forotherknownriskfactors,patientswith
diabetes had a 16% greater risk of devel-
oping atrial ﬁbrillation (hazard ratio [HR]
1.16 [95% CI 1.05–1.28]). However,
atrial ﬁbrillation risk associated with dia-
betes was substantially higher among
women(1.26[1.08–1.46])andwasnotsta-
tistically signiﬁcant among men (1.09
[0.96–1.24]). In addition, age 65 years
tripled the risk of atrial ﬁbrillation overall
Table 1—Baseline characteristics of patients with and without diabetes
Diabetes No diabetes P
n 17,372 17,372 —
Age (years) 58.4  11.5 58.4  11.5 —
Sex (% male) 51.2 51.2 —
Ethnicity (% nonwhite) 11.9 6.4 0.0001
Ever smoked (%) 22.2 25.4 0.0001
Diabetes duration (years) 2.6  3.8 — —
BMI (kg/m
2) 33.6  7.3 28.9  5.7 0.0001
Systolic blood pressure (mmHg) 136  19 132  18 0.0001
Diastolic blood pressure (mmHg) 80  10 79  10 0.0001
LDL cholesterol (mg/dl) 118  34 132  37 0.0001
HDL cholesterol (mg/dl) 44  13 52  16 0.0001
Triglycerides (mg/dl) 225  211 164  108 0.0001
Estimated glomerular ﬁltration rate (ml/min) 90  30 84  23 0.0001
A1C (%) 7.8  1.7 — —
Comorbidities (%)
Ischemic heart disease 10.6 9.8 0.014
History of stroke 4.4 2.9 0.0001
Valvular disease 1.7 1.7 0.834
Hypertension 47.1 26.9 0.0001
Heart failure 4.4 1.8 0.0001
History of depression 15.8 11.7 0.0001
Data are means  SD or %.
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whereasBMI30kg/m
2increasedatrialﬁ-
brillation risk among men but was not a
signiﬁcant predictor in the women only
model. White race, systolic blood pressure
140 mmHg, ischemic heart disease, val-
vular disease, hypertension, and heart fail-
ure were all signiﬁcantly associated with
atrial ﬁbrillation risk in both sexes.
CONCLUSIONS — In this observa-
tional, age- and sex-matched cohort, lon-
gitudinal study of 34,744 patients with
andwithoutdiabetes,wefoundthatatrial
ﬁbrillation was 44% more prevalent and
38% more likely to develop when diabe-
tes was present. Controlling for other
known risk factors such as hypertension
and heart failure approximately halved
the risk of incident atrial ﬁbrillation.
However, this ﬁnding differed between
men and women. Diabetes was not a sig-
niﬁcant predictor of atrial ﬁbrillation
amongmenaftercontrollingforotherrisk
factors but was highly signiﬁcant among
women.
Recent studies have provided evi-
dence of how comorbidities can have
important modulatory effects on the pro-
gressionandcomplicationsofatrialﬁbril-
lation (15). Thus far, studies evaluating
the speciﬁc role of diabetes have been
lacking. In the recent development of a
risk score for atrial ﬁbrillation, the Fra-
mingham Heart Study did not ﬁnd diabe-
tes to be a signiﬁcant predictor of atrial
ﬁbrillation risk (16). This ﬁnding is con-
trary to a previous Framingham report
that found diabetes to be a strong inde-
pendent risk factor (10). Consistent with
the latter study, our ﬁndings suggest that
in the present population, diabetes made
a signiﬁcant contribution to the preva-
lence and incidence of atrial ﬁbrillation,
independent of other established risk fac-
tors such as hypertension and congestive
heartfailure.Althoughthisresultneedsto
be conﬁrmed in other populations, there
may be important public health implica-
tions.Thesteadilyrisingprevalenceofdi-
abetes may further increase the
prevalence of atrial ﬁbrillation, already
the most common arrhythmia diagnosis
around the globe. Conversely, any efforts
made to prevent and treat diabetes may
reduce the burden of atrial ﬁbrillation.
Potential mechanisms
These ﬁndings also underscore the im-
portance of understanding the mechanis-
tic links responsible for this association.
Published studies point to abnormalities
oftheautonomicnervoussystemasbeing
animportantmechanismininitiationand
maintenance of atrial ﬁbrillation. In ob-
servational clinical studies, initiation of
atrial ﬁbrillation episodes have been as-
cribed to variations in autonomic tone
Figure 1—Prevalence of atrial ﬁbrillation by age and diabetes status. A: Data for all subjects. B:
Data for men only. C: Data for women only.
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tonomic tone have been made in condi-
tions such as sleep apnea (18). This work
has been extended in a canine model of
atrial ﬁbrillation in which researchers
have observed that discharges from the
stellategangliaandvagalnervesoftenpre-
cede the onset of paroxysmal atrial ﬁbril-
lation (19). In fact, targeted ablation of
these latter structures appears to prevent
the onset of paroxysmal atrial ﬁbrillation
indogs,andsuchtherapiesarebeingeval-
uated in humans (20–22). Analogous to
the well-described peripheral autonomic
neuropathy observed in diabetes, cardiac
autonomic neuropathy is a serious but
overlooked complication of diabetes
(23,24). Taken together, these ﬁndings
lend credence to the hypothesis that car-
diac autonomic dysfunction may be an
important mechanism for the increased
propensity for atrial ﬁbrillation in diabe-
tes and warrants further careful study.
The increased predilection for atrial
ﬁbrillation among female diabetic sub-
jects compared with male diabetic sub-
jects is a novel ﬁnding that needs to be
explored further. A prolonged intrinsic
QT interval is a well-recognized sex-
related difference in cardiac electrophys-
iological properties. Women have a
longer intrinsic QT interval, a phenome-
nonthathasbeenattributedtohigherlev-
els of estrogens affecting the cardiac
repolarizingpotassiumionchannels(25).
Although this ﬁnding is unlikely to affect
the propensity for atrial ﬁbrillation, there
could be other, yet undiscovered, sex dif-
ferencesinatrialionchannelpropertiesor
the remodeling of the autonomic tone in
female diabetic subjects that could ac-
count for the current observations.
Limitations
Anobservationalstudyhassomeinherent
limitations. In a subgroup of patients,
atrial ﬁbrillation is an asymptomatic and
paroxysmal phenomenon, such that it
mayescapedetectionunlessitisobserved
incidentally. It is possible that patients
with diabetes may be more likely to have
electrocardiograms or ambulatory moni-
toring in the absence of symptomatic
atrial ﬁbrillation compared with nondia-
betic patients. Conversely, diabetes is un-
diagnosed in 25% of individuals (1),
suggesting that the prevalence of diabetes
may have been underestimated in this
population. If so, we may be underesti-
mating the effect of diabetes on in-
creased prevalence of atrial ﬁbrillation
in this population. Finally, unmeasured
Figure 2—Cumulative age- and sex-adjusted incidence of atrial ﬁbrillation by diabetes status
amongpatientswhodidnothaveatrialﬁbrillationatbaseline.A:Dataforallsubjects.B:Datafor
men only. C: Data for women only.
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education, and alcohol intake could ac-
count for some of the differences we
report.
Summary
In conclusion, in this population, diabe-
tes was an independent determinant of
atrial ﬁbrillation prevalence and inci-
dence. Prevalence was higher at baseline
and there was an exaggerated increase of
atrial ﬁbrillation incidence over time in
diabetic versus nondiabetic patients.
Women with diabetes had an unex-
plained higher predilection for atrial ﬁ-
brillation compared with men. These
ﬁndings have potential public health im-
plications, especially in women, and em-
phasize the need for further investigation
of the mechanistic links between diabetes
and atrial ﬁbrillation.
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